Molecular Profile Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 43 of 43 entries

Molecular Profile	Indication/Tumor Type	Response Type	Relevant Treatment Approaches	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
RET M918T	medullary thyroid carcinoma	sensitive	RET Inhibitor	Cabozantinib	Guideline	Actionable	Cometriq (cabozantinib) is included in guidelines for patients with advanced or metastatic medullary thyroid carcinoma harboring RET M918T (PMID: 31549998, PMID: 35491008; ESMO.org).	31549998 detail... 35491008
RET M918T	medullary thyroid carcinoma	sensitive	RET Inhibitor	Cabozantinib	Phase III	Actionable	In a Phase III trial, Cometriq (cabozantinib) increased overall survival to 25.4 months in medullary thyroid carcinoma patients with RET M918T (J Clin Oncol 33, 2015, suppl; abstr 6012).	detail...
RET M918T	medullary thyroid carcinoma	sensitive	RET Inhibitor	Cabozantinib	Phase III	Actionable	In a Phase III trial, Cometriq (cabozantinib) treatment resulted in improved progression free survival (61 vs 17 weeks) compared to placebo in thyroid medullary carcinoma patients harboring RET M918T (PMID: 27525386).	27525386
RET M918T	medullary thyroid carcinoma	sensitive	RET Inhibitor	Pralsetinib	Phase Ib/II	Actionable	In a Phase I/II trial (ARROW), Gavreto (pralsetinib) treatment was well-tolerated, and resulted in an overall response rate (ORR) of 65% (51/79, 5% complete response, 59% partial response) in patients with advanced or metastatic medullary thyroid cancer harboring RET mutations, 61% of the patients harbored RET M918T (Ann Oncol. Vol 31, Supplement 4, S1084, Sep 1, 2020; NCT03037385).	detail...
RET M918T	medullary thyroid carcinoma	sensitive	RET Inhibitor	SY-5007	Phase I	Actionable	In a Phase I trial, SY-5007 treatment demonstrated safety and resulted in an objective response rate (ORR) of 57.8% (67/116, partial responses), a disease control rate (DCR) of 95.7% (111/116), and a median progression-free survival of 21.1 mo in advanced solid tumor patients harboring RET fusions or alterations, with an ORR of 52.2% (12/23) and DCR of 91.3% (21/23) at the phase II dose in medullary thyroid cancer patients harboring RET M918T (n=15) or other mutations (n=8) (PMID: 39489747; NCT05278364).	39489747
RET M918T	medullary thyroid carcinoma	predicted - sensitive		Everolimus	Case Reports/Case Series	Actionable	In a Phase II clinical trial, Afinitor (everolimus) treatment resulted in stable disease in 71% (5/7) of medullary thyroid cancer patients, and 4 of the 7 patients harbored a RET M918T mutation (PMID: 26294908; NCT01118065).	26294908
RET M918T	medullary thyroid carcinoma	predicted - sensitive	RET Inhibitor	Sorafenib	Case Reports/Case Series	Actionable	In a Phase II trial, Nexavar (sorafenib) treatment resulted in partial response in 10% (1/10) and stable disease in 90% (9/10) of patients with medullary thyroid carcinoma harboring RET M918T (PMID: 20368568; NCT00390325).	20368568
RET M918T	medullary thyroid carcinoma	sensitive	RET Inhibitor	Pralsetinib	Case Reports/Case Series	Actionable	In a Phase I trial, a patient with sporadic medullary thryoid cancer harboring RET M918T demonstrated a partial response, with maximal tumor reduction of 47% following treatment with Gavreto (pralsetinib) (PMID: 29657135; NCT03037385).	29657135
RET M918T	medullary thyroid carcinoma	sensitive	RET Inhibitor	Cabozantinib	Case Reports/Case Series	Actionable	In a clinical case study, Cometriq (cabozantinib) treatment resulted in a partial response in a patient with medullary thyroid carcinoma with extensive CNS metastasis harboring RET M918T, although the patient experienced multiple adverse effects and her disease progressed after 8 months of treatment (PMID: 33154983).	33154983
RET M918T	medullary thyroid carcinoma	sensitive	RET Inhibitor	Selpercatinib	Case Reports/Case Series	Actionable	In a clinical case study, Retevmo (selpercatinib) treatment resulted in rapid clinical improvement and complete resolution of the brain metastasis in a patient with metastatic medullary thyroid carcinoma harboring RET M918T whose disease progressed on prior Cometriq (cabozantinib) treatment, an official partial extracranial response was achieved at 1 year of treatment, until disease progression at 17 months (PMID: 33154983).	33154983
RET M918T	medullary thyroid carcinoma	sensitive	RET Inhibitor	Selpercatinib	Case Reports/Case Series	Actionable	In a clinical case study, a pediatric patient with previously treated metastatic medullary thyroid cancer harboring germ line RET M918T mutation achieved stable disease and remained on treatment after 5.2 months with Retevmo (selpercatinib) therapy (PMID: 32923911).	32923911
RET M918T	medullary thyroid carcinoma	sensitive	RET Inhibitor	MitoQ + Selpercatinib	Case Reports/Case Series	Actionable	In a clinical case study, treatment with the combination of Retevmo (selpercatinib) and MitoQ resulted in a partial response in a patient with medullary thyroid cancer harboring RET M918T, and in preclinical analysis, synergistically inhibited viability of a medullary thyroid cancer cell line harboring RET M918T in culture (PMID: 38378752).	38378752
RET M918T	thyroid gland carcinoma	predicted - sensitive	RET Inhibitor	Selpercatinib	Case Reports/Case Series	Actionable	In a clinical case study, Retevmo (selpercatinib) treatment resulted in a partial response after 9 weeks of treatment, with a decrease in the size of the cervical and mediastinal lymph nodes, in a patient with metastatic recurrent mixed medullary and follicular cell-derived thyroid carcinoma harboring RET M918T, and response was maintained at 33 weeks post-treatment initiation (PMID: 38647958).	38647958
RET M918T	malignant pheochromocytoma	predicted - sensitive	RET Inhibitor	Selpercatinib	Case Reports/Case Series	Actionable	In a Phase I/II trial (LIBRETTO-001), Retevmo (selpercatinib) treatment resulted in stable disease with progression-free survival for at least 56.3 months in a patient with metastatic pheochromocytoma harboring somatic RET M918T and resulted in a complete response by IRC assessment and partial response by investigator assessment in a second patient with concomitant pheochromocytoma and medullary thyroid carcinoma harboring germline RET M918T (PMID: 38661071;NCT03157128).	38661071
RET M918T	medullary thyroid carcinoma	sensitive	RET Inhibitor	Selpercatinib	Case Reports/Case Series	Actionable	In a clinical case study, Retevmo (selpercatinib) treatment resulted in a partial response in a pediatric patient with medullary thyroid carcinoma harboring RET M918T (PMID: 38844796; NCT03336931).	38844796
RET M918T	medullary thyroid carcinoma	sensitive	RET Inhibitor	Pz-1	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Pz-1 treatment inhibited downstream signaling and growth of a medullary thyroid carcinoma cell line harboring RET M918T in culture, and inhibited tumor growth in cell line xenograft models (PMID: 34373541).	34373541
RET M918T	Advanced Solid Tumor	sensitive	RET Inhibitor	ALW-II-41-27	Preclinical - Cell culture	Actionable	In a preclinical study, ALW-II-41-27 inhibited RET phosphorylation and downstream signaling, reduced proliferation of transformed cells expressing RET M918T in culture (PMID: 26046350).	26046350
RET M918T	medullary thyroid carcinoma	sensitive	RET Inhibitor	ALW-II-41-27	Preclinical - Cell culture	Actionable	In a preclinical study, ALW-II-41-27 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thryoid carcinoma cells harboring RET M918T in culture (PMID: 26046350).	26046350
RET M918T	medullary thyroid carcinoma	sensitive		AZD1480	Preclinical - Cell culture	Actionable	In a preclinical study, AZD1480 reduced phosphorylation of RET and downstream effectors, and inhibited growth and increased apoptosis of a medullary thyroid cancer cell line harboring RET M918T in culture (PMID: 23056499).	23056499
RET M918T	medullary thyroid carcinoma	sensitive	RET Inhibitor	Selpercatinib	Preclinical - Cell culture	Actionable	In a preclinical study, thyroid medullary carcinoma cells harboring RET M918T were sensitive to treatment with Retevmo (selpercatinib) in culture, demonstrating decreased cell proliferation (PMID: 29912274).	29912274
RET M918T	Advanced Solid Tumor	sensitive	RET Inhibitor	Selpercatinib	Preclinical - Cell culture	Actionable	In a preclinical study, cells expressing RET M918T were sensitive to treatment with Retevmo (selpercatinib) in culture, demonstrating decreased cell proliferation (PMID: 29912274).	29912274
RET M918T	Advanced Solid Tumor	sensitive	RET Inhibitor	Selpercatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Retevmo (selpercatinib) inhibited cell growth and Ret phosphorylation in transformed cells expressing RET M918T in culture (PMID: 33161056).	33161056
RET M918T	Advanced Solid Tumor	predicted - sensitive	RET Inhibitor	LOX-18228	Preclinical - Cell culture	Actionable	In a preclinical study, LOX-18228 treatment resulted in reduced viability in a cell line expressing RET M918T in culture (Cancer Res 2021;81(13_Suppl):Abstract nr 1464).	detail...
RET M918T	Advanced Solid Tumor	sensitive	RET Inhibitor	Pz-1	Preclinical - Cell culture	Actionable	In a preclinical study, Pz-1 treatment inhibited Ret phosphorylation and growth of transformed cells expressing RET M918T in culture (PMID: 34373541).	34373541
RET M918T	Advanced Solid Tumor	sensitive	RET Inhibitor	Selpercatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Retevmo (selpercatinib) inhibited Erk phosphorylation and growth of transformed cells expressing RET M918T in culture (PMID: 32284345).	32284345
RET M918T	Advanced Solid Tumor	sensitive	RET Inhibitor	Pralsetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gavreto (pralsetinib) inhibited Erk phosphorylation and growth of transformed cells expressing RET M918T in culture (PMID: 32284345).	32284345
RET M918T	Advanced Solid Tumor	sensitive	RET Inhibitor	Selpercatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Retevmo (selpercatinib) inhibited viability in transformed cells expressing RET M918T in culture (PMID: 36166639).	36166639
RET M918T	Advanced Solid Tumor	sensitive	RET Inhibitor	Pralsetinib	Preclinical - Cell culture	Actionable	In a preclinical study, Gavreto (pralsetinib) inhibited viability in transformed cells expressing RET M918T in culture (PMID: 36166639).	36166639
RET M918T	Advanced Solid Tumor	predicted - sensitive	RET Inhibitor	FHND5071	Preclinical - Cell culture	Actionable	In a preclinical study, FHND5071 inhibited Ret phosphorylation and proliferation in cells expressing RET M918T in culture (Cancer Res (2023) 83 (8_Supplement): LB330).	detail...
RET M918T	Advanced Solid Tumor	sensitive	RET Inhibitor	Vepafestinib	Preclinical - Cell culture	Actionable	In a preclinical study, Vepafestinib (TAS0953/HM06) inhibited proliferation of cells expressing RET M918T in culture (PMID: 37743366).	37743366
RET M918T	Advanced Solid Tumor	predicted - sensitive	RET Inhibitor	APS03118	Preclinical - Biochemical	Actionable	In a preclinical study, APS03118 treatment inhibited Ret phosphorylation in cells expressing RET M918T in culture (J Clin Oncol 40, no. 16_suppl (June 1, 2022)).	detail...
RET M918T	colorectal cancer	sensitive	RET Inhibitor	Sorafenib	Preclinical	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and decreased growth of colorectal cancer cells harboring a RET M918T mutation in culture (PMID: 17664273).	17664273
RET M918T	Advanced Solid Tumor	sensitive	RET Inhibitor	Sorafenib	Preclinical	Actionable	In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and decreased proliferation of cells expressing RET M918T in culture (PMID: 17664273).	17664273
RET M918T	thyroid gland carcinoma	sensitive	RET Inhibitor	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited RET signaling and decreased proliferation of thyroid carcinoma cells harboring a RET M918T mutation in culture (PMID: 23526464).	23526464
RET M918T	lung small cell carcinoma	sensitive	RET Inhibitor	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited growth of small cell lung carcinoma lines expressing RET M918T (PMID: 25122427).	25122427
RET M918T	lung small cell carcinoma	sensitive	RET Inhibitor	Vandetanib	Preclinical	Actionable	In a preclinical study, Caprelsa (vandetanib) inhibited growth of small cell lung carcinoma lines expressing RET M918T (PMID: 25122427).	25122427
RET M918T	Advanced Solid Tumor	sensitive	RET Inhibitor	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET M918T in culture (PMID: 23526464).	23526464
RET M918T	Advanced Solid Tumor	sensitive	RET Inhibitor	Vandetanib	Preclinical	Actionable	In a preclinical study, Caprelsa (vandetanib) inhibited Ret autophosphorylation and transforming activity in cells expressing RET M918T in culture (PMID: 15184865).	15184865
RET M918T	Advanced Solid Tumor	sensitive	RET Inhibitor	HG-6-63-01	Preclinical	Actionable	In a preclinical study, HG-6-63-01 inhibited RET phosphorylation and downstream signaling and reduced proliferation of transformed cells expressing RET M918T in culture (PMID: 26046350).	26046350
RET M918T	Advanced Solid Tumor	sensitive	RET Inhibitor	XMD15-44	Preclinical	Actionable	In a preclinical study, XMD15-44 inhibited RET phosphorylation and downstream signaling and reduced proliferation of transformed cells expressing RET M918T in culture (PMID: 26046350).	26046350
RET M918T	medullary thyroid carcinoma	sensitive	RET Inhibitor	HG-6-63-01	Preclinical	Actionable	In a preclinical study, HG-6-63-01 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thyroid carcinoma cells harboring RET M918T in culture (PMID: 26046350).	26046350
RET M918T	medullary thyroid carcinoma	sensitive	RET Inhibitor	XMD15-44	Preclinical	Actionable	In a preclinical study, XMD15-44 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thyroid carcinoma cells harboring RET M918T in culture (PMID: 26046350).	26046350
RET M918T	Advanced Solid Tumor	sensitive	RET Inhibitor	Pz-1	Preclinical	Actionable	In a preclinical study, Pz-1 inhibited Ret phosphorylation in transformed cells expressing RET M918T (PMID: 26126987).	26126987

Showing 1 to 43 of 43 entries

Filter rows:

Profile Name	RET M918T
Gene Variant Detail	RET M918T (gain of function)
Relevant Treatment Approaches	RET Inhibitor

Molecular Profile Detail

Contact

Filtering

Sorting